J2265 Minocycline Injection HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS Level II J2265: Injection, Minocycline Hydrochloride, 1 mg

HCPCS Level II code J2265 denotes an injectable formulation of minocycline hydrochloride measured per 1 mg unit. As an HCPCS Level II drug code, J2265 is used on medical claims to identify the specific medication administered rather than the administration procedure itself. Accurate coding for injectable antimicrobials like minocycline is important for drug utilization tracking, payer adjudication, and consistent reimbursement across outpatient settings.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for minocycline injection, typical sites of service where this code is billed, and the role of HCPCS Level II drug codes in claims processing. The publication also outlines common billing considerations, relevant benchmarking categories, and any notable policy or reimbursement factors affecting injectable antibiotic codes.

This summary is intended for coding professionals, revenue cycle staff, and policy analysts seeking a national perspective on billing practice and payer coverage for injectable minocycline.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ2265HCPCS Level IIminocyclineinjectable medicationdrug codingoutpatient infusionantibioticmedical billingpharmacy billing

Billing Code Overview

HCPCS Level II code J2265 describes an injection of minocycline hydrochloride, 1 mg. This code represents the drug formulation and the unit dosage for an injectable antibiotic preparation.

Service Type: Drug administration (injectable medication)

Typical Site of Service: Outpatient settings where injectable antimicrobials are administered, such as physician offices, outpatient infusion centers, and hospital outpatient departments.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 32-year-old female presents to an outpatient dermatology clinic with a nodular inflammatory acneiform eruption unresponsive to multiple oral antibiotic courses and topical therapies. The dermatology provider elects to administer an intralesional injection of minocycline hydrochloride to treat localized, recalcitrant inflammatory nodules. The patient is consented, allergy status confirmed (no tetracycline allergy, not pregnant), and vital signs obtained. The provider performs antiseptic skin preparation, uses a small-gauge needle to inject the indicated milligram dose of J2265 (minocycline hydrochloride, 1 mg per unit) directly into the lesion or into the affected subcutaneous tissue. Post-injection, the site is observed for immediate reaction for 15–30 minutes, after which the patient receives written aftercare instructions and scheduling for follow-up.

Typical site of service: outpatient dermatology clinic or ambulatory procedure suite.

Common clinical workflow steps:

Patient evaluation and confirmation of indication
Consent and allergy/pregnancy check
Preparation of medication and documentation of quantity billed in mg/units of J2265
Aseptic administration (intralesional or subcutaneous) at the lesion site
Post-procedure observation and discharge with aftercare instructions

Coding Specifications

HCPCS J2410: Oxymorphone Injection, Up to 1 mg

HCPCS-J7312-DEXAMETHASONE-INTRAVITREAL-IMPLANT-01-MG

HCPCS J7312: Dexamethasone Intravitreal Implant, 0.1 mg

HCPCS-J1562-IMMUNE-GLOBULIN-VIVAGLOBIN-INJECTION-100MG

HCPCS Level II J1562: Immune Globulin (Vivaglobin) Injection, 100 mg

HCPCS-J0608-LANTHANUM-CARBONATE-ORAL-POWDER-5MG

HCPCS Level II J0608: Lanthanum Carbonate Oral Powder, 5 mg

HCPCS-J0887-EPOETIN-BETA-INJECTION-ESRD-DIALYSIS

HCPCS J0887: Epoetin Beta Injection for ESRD on Dialysis

HCPCS-J7193-FACTOR-IX-NON-RECOMBINANT-PER-IU

HCPCS J7193: Factor IX (non-recombinant) per IU

HCPCS-J7637-DEXAMETHASONE-INHALATION-SOLUTION-COMPOUNDED-DME

HCPCS J7637: Dexamethasone Inhalation Solution, Compounded, per mg

HCPCS-J1817-INSULIN-FOR-INSULIN-PUMP-PER-50-UNITS

HCPCS Level II J1817: Insulin for Insulin Pump, per 50 Units

HCPCS-J7309-METHYL-AMINOLEVULINATE-TOPICAL-16-8-1G

HCPCS J7309: Methyl Aminolevulinate Topical 16.8% 1g

HCPCS-J7518-MYCOPHENOLIC-ACID-ORAL-180-MG

HCPCS Level II J7518: Mycophenolic Acid, Oral, 180 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207N00000X`	Dermatology	Primary specialty performing intralesional minocycline for acneiform or inflammatory skin lesions.
`208000000X`	Family Medicine	May perform outpatient injectable procedures for skin infections or inflammatory lesions.
`208D00000X`	Internal Medicine	Provides outpatient injections for certain dermatologic conditions in general practice.
`363L00000X`	Physician Assistant	APPs frequently administer office-based injections under supervising physician.
`163W00000X`	Clinical Nurse Specialist	Advanced practice nurses in dermatology or outpatient clinics who may perform injections.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L70.0`	Acne vulgaris	Primary indication for intralesional antibiotic injections for nodular or cystic inflammatory lesions.
`L70.1`	Acne conglobata	Severe nodulocystic acne where intralesional therapy may be an adjunctive treatment.
`L98.9`	Disorder of skin and subcutaneous tissue, unspecified	Used when a more specific diagnosis is not established but injection is indicated for localized inflammatory skin disease.
`L03.90`	Cellulitis, unspecified	May be relevant when local injections are used in select inflammatory or infectious contexts with dermatologic consultation.
`B37.2`	Candidal intertrigo	Included as a differential when localized inflammatory lesions are being treated; not a primary indication for minocycline injection but part of clinical consideration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, moderate severity	Common pre-procedure E/M for assessment, consent, and decision to administer intralesional minocycline.
`20610`	Arthrocentesis, aspiration and/or injection; major joint or bursa (e.g., shoulder, hip)	Not typically used for cutaneous injections but listed as a standard injection code for deeper musculoskeletal injections when documentation supports.
`11900`	Injection, intralesional; up to and including 0.5 mL	Used for billing intralesional injections of medications into skin lesions when units align with volume-based CPT reporting.
`10060`	Incision and drainage of abscess; simple or single	May be performed before or instead of injection for infected nodules requiring drainage.
`99070`	Supplies and materials (except spectacles), provided by the physician over and above those usually included with office visit or procedure	Used to report supplies related to the injection when payer policy permits separate supply billing.

`JW`	Drug amount discarded/not administered	Use when part of a single-dose vial is discarded and documentation supports wastage for multi-dose billing situations.
`JZ`	No drug administered from single-dose vial	Use when no drug was administered from a prepared single-dose vial but billing rules require reporting.
`QX`	Certified nurse midwife/physician assistant/assistant at surgery modifier X	Use when the service is performed by an eligible non-physician practitioner with appropriate supervision or scope.
`QY`	Service furnished by a physician under a teaching physician’s primary care exception	Use when a teaching physician bills under the primary care exception and a trainee participates.
`JW`	Drug amount discarded/not administered	Use when partial vial wastage must be reported (note: listed again for emphasis on common applicability).
`62`	Two surgeons	Use when two surgeons of different specialties share responsibility for the procedure site (rare for injections).
`80`	Assistant surgeon	Use when an assistant surgeon is required and documented (uncommon for intralesional injections).
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare-assigned services	Use when an APP performs the injection and Medicare billing requires this modifier per local guidance.
`23`	Unusual anesthesia	Use when significant, medically necessary anesthesia beyond local infiltration is required for the procedure.
`22`	Unusual procedural services	Use when the service is significantly greater in complexity or time than typical injection and documentation supports increased work.
`52`	Reduced services	Use when a component of the service is intentionally reduced or not completed.
`78`	Return to operating/procedure room for related procedure during postoperative period	Use when the patient returns to the procedure room for a related complication or additional treatment in the postoperative period.
`59`	Distinct procedural service (not listed in raw modifiers but commonly relevant)	Data not available in the input.

OpenPayer